Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Dividend Updates

 The Board of Directors at its Meeting held on May 26, 2023 had discussed and approved the following inter-alia along with other items: 1. Audited Standalone and Consolidated financial results for the Half year and Year ended March 31, 2023, together with the auditors' report thereon. 2. Recommend final dividend for the year ended March 31, 2023- it was unanimously decided that this agenda shall be taken and resolved upon at a future date.
26-05-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Outcome Of The Meeting Of Board Of Directors Of The Company Held On May 26, 2023.

 The Board of Directors at its Meeting held on May 26, 2023 had discussed and approved the following inter-alia along with other items: 1. Audited Standalone and Consolidated financial results for the Half year and Year ended March 31, 2023, together with the auditors' report thereon.
26-05-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of The Company Held On May 26, 2023

 The Board of Directors at its Meeting held on May 26, 2023 had discussed and approved the following: 1. Audited Standalone and Consolidated financial results for the Half year and Year ended March 31, 2023, with the auditors' report. 2. Recommend final dividend for the year ended March 31, 2023- it was unanimously decided that this agenda shall be taken and resolved upon at a future date. 3. Approval of related party transactions subject to approval of the members. 4. The appointment of M/s Uttam Nahar & CO., Chartered Accountants, Mumbai, as an Internal Auditor for the FY 2023-2024. 5. The appointment of M/s Vishal N. Manseta, Practicing Company Secretaries, Mumbai as Secretarial Auditor of the Company for the FY 2022-2023. 6. Increase in remuneration of Mr. Hemal Mehta, the Managing Director of the Company subject to approval of members. 7. Increase in remuneration of Mr. Sachin Mehta, the Joint Managing Director of the Company subject to approval of the members.
26-05-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Board Meeting Intimation for The Half-Year And Year Ended March 31, 2023.

 Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2023 ,inter alia, to consider and approve 1. the Audited Standalone & Consolidated financial results for the Half-year & Year ended March 31, 2023, 2. to recommend Final Dividend to the equity shareholders of the Company for the Financial Year 2022-2023. & to consider and discuss any other matter.
20-05-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Sudarshan Pharma Industries Ltd 2 CIN NO. U51496MH2008PLC184997 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 0 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)0 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-ISHITA ASHOK SAMANIDesignation :-COMPLIANCE OFFICER COMPANY SECRETARY Name of the Chief Financial Officer :- DHARAM VINOD JILKA Designation : -CHIEF FINANCIAL OFFICER Date: 28/04/2023
28-04-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySudarshan Pharma Industries Ltd 2CIN NO.U51496MH2008PLC184997 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 30.58 4Highest Credit Rating during the previous FY BBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: ISHITA ASHOK SAMANI Designation: COMPLIANCE OFFICER COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: DHARAM VINOD JILKA Designation: CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
28-04-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Compliance Certificate Pursuant To Reg. 7(3) Of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

 Sudarshan Pharma Industries Limited intimates the Stock Exchange regarding Compliance Certificate pursuant to Reg. 7(3) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015
28-04-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Certificate Pursuant To Reg. 40(9) & 40(10) Of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

 Sudarshan Pharma Industries Limited intimates the Exchange regarding the Certificate pursuant to Reg. 40(9) & 40(10) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015
28-04-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Sudarshan Pharma Industries Limited intimates the Stock Exchange regarding Certificate under Regulation 74(5) of SEBI of (Depository and Participants) Regulations, 2018 for the quarter ended March 31, 2023.
20-04-2023
Bigul

Sudarshan Pharma Industries Ltd - 543828 - Closure of Trading Window

 Sudarshan Pharma Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
29-03-2023
Next Page
Close

Let's Open Free Demat Account